Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Review

Approach to the patient with atypical diabetes

Devin W. Steenkamp, Sara M. Alexanian and Elliot Sternthal
CMAJ June 10, 2014 186 (9) 678-684; DOI: https://doi.org/10.1503/cmaj.130185
Devin W. Steenkamp
Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center, and Boston University School of Medicine, Boston, Mass.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: devin.steenkamp@bmc.org
Sara M. Alexanian
Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center, and Boston University School of Medicine, Boston, Mass.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elliot Sternthal
Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center, and Boston University School of Medicine, Boston, Mass.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading
Submit a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
References
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Minimum 7 characters.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'. Minimum 12 characters.
Your organization, institution's or residential address.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

  • Re:Atypical diabetes: clarifying the muddy waters
    Devin W. Steenkamp
    Posted on: 08 August 2014
  • Atypical diabetes: clarifying the muddy waters
    Elizabeth AC Sellers
    Posted on: 07 July 2014
  • Posted on: (8 August 2014)
    Page navigation anchor for Re:Atypical diabetes: clarifying the muddy waters
    Re:Atypical diabetes: clarifying the muddy waters
    • Devin W. Steenkamp
    • Other Contributors:

    We would like to thank Dr Sellers and colleagues for their thoughtful letter in response to our recent article and for drawing attention to the Canadian diabetes landscape.

    This article was written for the practicing primary care clinician, who may occasionally take care of a patient with diabetes who doesn't seem to fit into our typical diabetes classification paradigm. We recognize that much still needs to be l...

    Show More

    We would like to thank Dr Sellers and colleagues for their thoughtful letter in response to our recent article and for drawing attention to the Canadian diabetes landscape.

    This article was written for the practicing primary care clinician, who may occasionally take care of a patient with diabetes who doesn't seem to fit into our typical diabetes classification paradigm. We recognize that much still needs to be learned and we specifically intended to avoid onerous detail and have deliberately not attempted to provide a comprehensive review of the topic for the expert practicing endocrinologist. Our intent was to highlight phenotypic features and the limitations of lumping diverse groups of patients together - directed at the general physician. We aimed to emphasize the value in looking beyond our usual classification paradigm.

    As such, we also attempted to avoid unnecessary complexity and controversy that may further 'muddy" the already complex waters. We agree that LADA is a slowly progressive form of type 1a diabetes, and while it may not be distinct from type 1 diabetes, it has certain autoimmune and phenotypic features that distinguish it from childhood type 1 diabetes. It is also the most common presentation of autoimmune diabetes in adults and therefore may initially be confused with type 2 diabetes. However, ketosis prone diabetes is not simply type 2 diabetes presenting with ketoacidosis. This group of patients is still poorly understood and much work needs to be done in furthering our understanding of the basic pathophysiology, of what constitutes this heterogeneous group of diabetes. For example, emerging metabolomics data suggest that in individuals within certain subsets of KPD, a distinctive novel pathogenic process of defective energy production and ketosis may be at play. (Patel SG et al, Diabetes 2013 Mar; 62(3):912-22.)

    As adult endocrinologists, we have written this article from an adult medicine perspective and have not specifically intended to exclude important pediatric literature - and we thank the letter writer's for drawing attention to the pediatric population. We also specifically selected the three atypical diabetes phenotypes that were reviewed in this article, as we believe these are most likely to be encountered in a general primary care setting. Given space limitations, we were unable to describe specific populations with monogenic diabetes, but we hope that our focused discussion of HNF1A monogenic diabetes will stimulate consideration of this type of diabetes.

    There are certainly many more atypical diabetes phenotypes to be considered and we agree that regional variation and location of practice are highly relevant. For example, in our hospital, which serves a large, under-served, heterogeneous urban population, ketosis prone diabetes is the most common reason for admission to the medical ICU with ketoacidosis. Type 1a diabetes is less common in our particular setting. In terms of the comment that we did not specifically discuss differences in prevalence in type 2 diabetes by ethnicity, we acknowledge these differences exist.

    While we recognize the increasing burden of obesity in both adults and children, the literature (including the citation included by the letter writers) does support that most patients diagnosed with type 1 diabetes and HNF1A diabetes continue to be lean at diagnosis. We recognize that this may change in future, but for the purposes of helping to provide general physicians with clinical phenotypic clues to aid diagnosis, we believe there is value in this distinction.

    Naturally, diet and lifestyle modification form the cornerstone of all diabetes therapeutics and we agree that metformin is the initial "pharmacologic" therapy for type 2 diabetes in most in individuals. The use of the terminology "classic juvenile form of diabetes" to describe type 1 diabetes was included for those physicians who may be more familiar with the older terminology.

    We acknowledge that controversies surrounding diabetes classification continue to exist, but recognition of a possible atypical diabetes phenotype is an important part of primary diabetes care.

    Devin Steenkamp, MD.

    Sara Alexanian, MD.

    Elliot Sternthal, MD.

    Section of Endocrinology, Diabetes and Nutrition,

    Boston University School of Medicine

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
  • Posted on: (7 July 2014)
    Page navigation anchor for Atypical diabetes: clarifying the muddy waters
    Atypical diabetes: clarifying the muddy waters
    • Elizabeth AC Sellers, Associate Professor
    • Other Contributors:

    We are writing this letter in response to the recent review by Drs. Steenkamp, Alexanian and Sternthal entitled "Approach to the Patient with Atypical Diabetes" published in the Canadian Medical Association Journal, June 10, 2014 [1]. The authors present their approach to the diagnostic challenge presented by "atypical" diabetes. As the authors clearly state, our improved understanding of the pathophysiology of diabetes...

    Show More

    We are writing this letter in response to the recent review by Drs. Steenkamp, Alexanian and Sternthal entitled "Approach to the Patient with Atypical Diabetes" published in the Canadian Medical Association Journal, June 10, 2014 [1]. The authors present their approach to the diagnostic challenge presented by "atypical" diabetes. As the authors clearly state, our improved understanding of the pathophysiology of diabetes mellitus has increased the complexity and challenge associated with accurate diagnosis of a patient's type of diabetes. We acknowledge the importance of understanding each individual's pathophysiology to tailor their treatment.

    The authors' stated goal was "to provide a practical approach to the heterogenous group of disorders..." Unfortunately, we believe that the authors have not successfully achieved this goal. We have several concerns about the content of this review particularly in the context of the Canadian diabetes landscape.

    There is no discussion in the review around the controversy that surrounds the diagnoses of "ketosis-prone diabetes" and "latent-autoimmune diabetes of adulthood". Many clinicians believe these are not separate entities but are within the spectrum of type 2 diabetes and type 1 diabetes, respectively. In this manuscript, there is no mention of the occurrence of diabetic ketoacidosis in both adults and children with type 2 diabetes. This has been well published over the last 2 decades in both adults and children [2-4] and likely represents what the authors refer to as "ketosis prone diabetes".

    Moreover, the authors use somewhat dated terminology, such as "the classic juvenile form of diabetes". Both the Canadian Diabetes Association and the American Diabetes Association discontinued the use of this terminology more than 15 years ago. Continued use of this terminology, albeit tempered by "now known as type 1 diabetes," perpetuates the confusion related to terminology.

    A clearer distinction between diabetes in adult versus pediatric populations would be beneficial throughout the article for the readers of the CMAJ. Much of the data presented and literature cited pertains to adults only. For example, Table 2 defines "lean" as a BMI <25 kg/m2, an adult criterion. The Canadian Diabetes Association has worked hard to provide useful age- specific definitions and management guidelines; these are available on-line for health care providers [5].

    Additionally, the authors state that both type 1 diabetes and HNF1 alpha transcription factor diabetes occur predominately in lean populations. Clinicians can no longer rely on this phenotype to help us to distinguish type of diabetes, given the increasing prevalence of overweight and obesity in the general population [6].

    Table 1 refers to genetic "penetrance". This typically pertains to a monogenic disorder and refers to individuals who inherit the gene mutation and the percentage of these individuals who manifest physical signs or symptoms of the disorder [7]. It is therefore not clear to us how percentage penetrance for polygenic disorders can be reported. Table 1 also reports that type 2 diabetes has a high prevalence worldwide. While type 2 diabetes is a global disease, there are clear ethnic predispositions to this disorder [8, 9].

    The authors state that metformin is first line therapy for most patients with type 2 diabetes. This is not consistent with the Canadian Diabetes Association Clinical Practice Guidelines where lifestyle modification is first line therapy in children and also in adults (with consideration to the use of metformin in addition to lifestyle modification at diagnosis in adults) [9,10]. Perhaps this should have been clarified that metformin would be the first line pharmacotherapeutic agent.

    Our location of practice may bias us, but given the review's publication in the journal of the Canadian Medical Association, mention of the polymorphism of the HNF 1 alpha gene found in the Oji-Cree of northeastern Manitoba and northwestern Ontario is warranted. This polymorphism contributes to the development of type 2 diabetes in the Oji- Cree, who have amongst the highest reported rates of type 2 diabetes in both adults and youth [11,12]. The authors provided a brief overview of MODY2 and 3; however regional differences are important to reinforce to ensure optimal diagnoses and intervention.

    We agree with the authors that there are many important reasons to differentiate diabetes types, to guide treatment, prognosis and genetic counseling. This is an ongoing area of active research and knowledge translation. We trust that this letter has helped to augment your readers' understanding of diabetes in Canada, for all age groups.

    Sincerely,

    Elizabeth Sellers, MD., MSc., FRCPC Associate Professor

    Seth Marks, MD., MSc., FRCPC Associate Professor

    Celia Rodd MD., MD., MSc., FRCPC Associate Professor

    Brandy Wicklow MD., MSc., FRCPC Assistant Professor

    Heather Dean MD., FRCPC Professor

    Section of Pediatric Endocrinology & Metabolism Department of Pediatrics and Child Health University of Manitoba

    References

    1. Steenkamp DW, Alexanian SM, Sternthal E. Approach to the patient with atypical diabetes. CMAJ 2014;186; 678-684.

    2. Newton CA, Raskin P. Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus. Arch Intern Med 2004; 164: 1925-1931.

    3. Rewers A, Klingensmith G, Davis C et al. Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for Diabetes in Youth Study. Pediatrics 2008; 121: 1258-1266.

    4. Amed S, Dean HJ, Panagiotopoulos C, et al. Type 2 diabetes, medication-induced diabetes and monogenic diabetes in Canadian children: a prospective national surveillance study. Diabetes Care 2010;33:786-91.

    5. http://www.diabetes.ca/clinical-practice-education/clinical- practice-guidelines

    6. Kaminski BM, Klingensmith GJ, Beck RW, Tamborlane WV, Lee J, Hassan K, Schtz D, Kollman C, Redondo MJ. Body mass index at the time of diagnosis of autoimmune type 1 diabetes in children. J Peds 2013; 162: 736 -740.

    7. Nussbaum RL, McInnes RR, Willard HF. Thompson and Thompson: Genetics in Medicine 7th edition 2007. Saunders, Philadelphia, PA

    8. Ekoe JM, Punthakee Z, Ransome T, Prebtani APH, Goldenberg R. Screening for type 1 and type 2 diabetes. Can J Diabetes 2013; 37: S8-S11.

    9. Panagiotopoulos C, Riddell MC, Sellers EAC. Type 2 diabetes in children and adolescents. Can J Diabetes 2013; 37: S163-S167.

    10. Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, Sherifali D, Woo V, Yale JF. Pharmacologic management of type 2 diabetes. Can J Diabetes 2013;37: S61-S68.

    11. Hegele RA, Zinman B, Hanley AJ, Harris SB, Barrett PH, Cao H. Genes, environment and Oji-Cree type 2 diabetes. Clin Biochem 2003; 36: 163-170.

    12. Dean HJ, Young TK, Flett B, Wood-Steiman P. Screening for type-2 diabetes in aboriginal children in northern Canada. The Lancet. 1998;352(9139):1523-1524.

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 186 (9)
CMAJ
Vol. 186, Issue 9
10 Jun 2014
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Approach to the patient with atypical diabetes
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Approach to the patient with atypical diabetes
Devin W. Steenkamp, Sara M. Alexanian, Elliot Sternthal
CMAJ Jun 2014, 186 (9) 678-684; DOI: 10.1503/cmaj.130185

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Approach to the patient with atypical diabetes
Devin W. Steenkamp, Sara M. Alexanian, Elliot Sternthal
CMAJ Jun 2014, 186 (9) 678-684; DOI: 10.1503/cmaj.130185
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • General diagnostic considerations
    • Monogenic diabetes
    • Ketosis-prone diabetes
    • Latent autoimmune diabetes of adulthood
    • Conclusion
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights
  • PubMed
  • Google Scholar

Cited By...

  • Uncommon Presentations of Diabetes: Zebras in the Herd
  • Atypical diabetes: clarifying the muddy waters
  • Google Scholar

More in this TOC Section

  • Diagnosis and management of postural orthostatic tachycardia syndrome
  • A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes
  • Prevention and management of hyperkalemia in patients treated with renin–angiotensin–aldosterone system inhibitors
Show more Review

Similar Articles

Collections

  • Topics
    • Diabetes
    • Genetics
    • Screening & diagnostic tests

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire